Literature DB >> 20801900

Highly active antiretroviral therapy alone may be an effective treatment for HIV-associated multi-centric Castleman's disease.

Siow Ming Lee, Simon G Edwards, Daniella N Chilton, Alan Ramsay, Robert F Miller.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20801900      PMCID： PMC2966925          DOI： 10.3324/haematol.2010.027441

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS.

Authors:  C Zietz; J R Bogner; F D Goebel; U Löhrs
Journal:  N Engl J Med       Date:  1999-06-17       Impact factor: 91.245

2.  Successful treatment of AIDS-related Castleman's disease following the administration of highly active antiretroviral therapy (HAART).

Authors:  E Sprinz; M Jeffman; P Liedke; A Putten; G Schwartsmann
Journal:  Ann Oncol       Date:  2004-02       Impact factor: 32.976

3.  Prolonged remission of HIV-associated multicentric Castelman's disease with an anti-CD20 monoclonal antibody as primary therapy.

Authors:  Frédéric Marrache; Claire Larroche; Nathalie Mémain; Olivier Bouchaud; Michel Robineau; Olivier Hermine; Olivier Lortholary
Journal:  AIDS       Date:  2003-06-13       Impact factor: 4.177

4.  Sustained high levels of serum HHV-8 DNA years before multicentric Castleman's disease despite full suppression of HIV with highly active antiretroviral therapy.

Authors:  Rianne Baatenburg de Jong; Philip M Kluin; Stefano Rosati; Paul L van Haelst; Herman G Sprenger; Dick Johan van Spronsen
Journal:  AIDS       Date:  2003-06-13       Impact factor: 4.177

5.  Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.

Authors:  M Corbellino; G Bestetti; C Scalamogna; S Calattini; M Galazzi; L Meroni; D Manganaro; M Fasan; M Moroni; M Galli; C Parravicini
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

6.  Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients.

Authors:  E Oksenhendler; M Duarte; J Soulier; P Cacoub; Y Welker; J Cadranel; D Cazals-Hatem; B Autran; J P Clauvel; M Raphael
Journal:  AIDS       Date:  1996-01       Impact factor: 4.177

7.  KSHV- and EBV-associated germinotropic lymphoproliferative disorder.

Authors:  Ming-Qing Du; Tim C Diss; Hongxiang Liu; Hongtao Ye; Rifat A Hamoudi; José Cabeçadas; Henry Y Dong; Nancy Lee Harris; John K C Chan; John W Rees; Ahmet Dogan; Peter G Isaacson
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

8.  Successful treatment of Castleman's disease with HAART in two HIV-infected patients.

Authors:  M Lanzafame; G Carretta; M Trevenzoli; L Lazzarini; S Vento Ercole Concia
Journal:  J Infect       Date:  2000-01       Impact factor: 6.072

9.  Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial.

Authors:  Laurence Gérard; Alice Bérezné; Lionel Galicier; Véronique Meignin; Martine Obadia; Nathalie De Castro; Christine Jacomet; Renaud Verdon; Isabelle Madelaine-Chambrin; Emmanuelle Boulanger; Sylvie Chevret; Felix Agbalika; Eric Oksenhendler
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

10.  Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection.

Authors:  C Simonelli; R Tedeschi; A Gloghini; R Talamini; M T Bortolin; M Berretta; M Spina; S Morassut; E Vaccher; P De Paoli; A Carbone; U Tirelli
Journal:  J Med Virol       Date:  2009-05       Impact factor: 2.327
View more
  4 in total

1.  HIV-associated multicentric Castleman's disease after initiation of antiretroviral therapy: experience of a European centre.

Authors:  J Katchanov; U Zimmermann; G Branding; K Arastéh; M Müller
Journal:  Infection       Date:  2014-03-04       Impact factor: 3.553

Review 2.  HIV-associated multicentric Castleman disease.

Authors:  Deepa Reddy; Ronald Mitsuyasu
Journal:  Curr Opin Oncol       Date:  2011-09       Impact factor: 3.645

3.  Multicentric Castleman's disease in a Ghanaian adult.

Authors:  Y A Dei-Adomakoh; C Segbefia; I Ekem; A Taylor
Journal:  Ghana Med J       Date:  2013-06

4.  A delayed diagnosis: conflicting investigation results should be challenged.

Authors:  D Mital; V Desai
Journal:  Case Rep Pathol       Date:  2011-09-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.